FutureWorld (FWDG) 10-Q 17 Feb 15 2015 Q3 Quarterly report Financial data

Document_And_Entity_Informatio

Document And Entity Information	9 Months Ended
	Dec. 31, 2014
Document And Entity Information [Abstract]
Entity Registrant Name	FUTUREWORLD CORP.
Entity Central Index Key	1273988
Trading Symbol	fwdg
Current Fiscal Year End Date	-28
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding	860,645,439
Document Type	10-Q
Document Period End Date	31-Dec-14
Amendment Flag	FALSE
Document Fiscal Year Focus	2015
Document Fiscal Period Focus	Q3

CONSOLIDATED_BALANCE_SHEETS

CONSOLIDATED BALANCE SHEETS (USD $)	Dec. 31, 2014	Mar. 31, 2014
Current assets
Cash	$150,794	$2,000
Accounts receivable	544,131	0
Related party receivables
Inventory	37,931	0
Note receivable	0	0
Total current assets	732,856	2,000
Property & equipment, net of accumulated - net	974
Intangible property, net of accumulated - net	94,169
Land	60,000
Deposits	2,205	0
Total Assets	890,204	2,000
Current liabilities
Accounts payable	47,343	6,350
Accrued expenses	1,292,781	1,089,530
Notes Payable	520,574	0
Loans and notes payable, related parties	189,017	277,338
Total current liabilities	2,049,715	1,373,218
Notes payable to shareholder	0	0
Total liabilities	2,049,715	1,373,218
Stockholders' Equity
Preferred stock, $.0001 par value, 100,000,000 shares authorized, none issued
Common stock, $.0001 par value, 1,900,000,000 shares authorized, and; 453,973,966 and 446,373,966 shares issued and outstanding, respectively	45,517	44,637
Additional paid-in capital	5,655,296	4,647,567
Minority interest in subsidiary	0
Accumulated deficit	-6,860,324	-6,063,422
Total stockholders' equity	-1,159,511	-1,371,218
Total Liabilities and Stockholders' Equity	$890,204	$2,000

CONSOLIDATED_BALANCE_SHEETS_Pa

CONSOLIDATED BALANCE SHEETS (Parentheticals) (USD $)	Dec. 31, 2014	Mar. 31, 2014
Statement of Financial Position [Abstract]
Preferred stock, par value (in dollars per share)	$0.00	$0.00
Preferred stock, shares authorized	100,000,000	100,000,000
Preferred stock, shares issued
Common stock, par value (in dollars per share)	$0.00	$0.00
Common stock, shares authorized	1,900,000,000	1,900,000,000
Common stock, shares issued	453,973,966	446,373,966
Common stock, shares outstanding	453,973,966	446,373,966

Consolidated_Statements_of_Ope

Consolidated Statements of Operations (unaudited) (USD $)	3 Months Ended		9 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2014	Dec. 31, 2013
Income Statement [Abstract]
Revenues	$362,416		$440,188
Direct costs	6,763		44,297
Gross Profit	355,653		395,891
Operating expenses:
Salaries and benefits	124,296	39,132	354,578	146,055
Consulting
Professional fees	44,071	1,180	259,472	38,949
General and administrative	199,086		271,768
Amortization and depreciation	112,304	9,870	115,109	42,810
Total operating expenses	479,757	50,182	1,000,927	190,312
Other income (expense):
Interest expenses	-43,892	-2,548	-211,506	-18,365
Sale of assets, net
Total other (expense)	-43,892	-2,548	-211,506	-18,365
Loss from operations before income taxes	-167,996	-52,730	-816,542	-208,677
Provision for income taxes	0
Loss from operations before minority interest	-167,996	-52,730	-816,542	-208,677
Minority Interest	0
Net loss	($167,996)	($52,730)	($816,542)	($208,677)
Earnings (loss) per share:
Basic (in dollars per share)	$0	$0	$0	$0
Weighted average shares outstanding
Basic (in shares)	465,934,785	416,373,966	454,417,158	416,373,966

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (unaudited) (USD $)	9 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Cash Flows from Operating Activities:
Net (loss) income	($816,542)	($208,677)
Adjustment to reconcile Net Income to net cash provided by operations:
Depreciation and amortization	112,304	42,810
Stock based compensation	121,592	0
Amortization of debt discount	210,784	0
Changes in assets and liabilities:
Accounts receivable	-544,131
Notes receivable
Inventory	-37,931
Due from affiliate
Related party loans		-175,182
Prepaid and other
Accounts payable	40,993	-1,922
Accrued expenses	203,251	-76,848
Net Cash (Used) Provided by Operating Activities	-709,680	-419,819
Cash flows from Investing Activities:
Other	-2,205
Net Cash (Used) Provided by investing Activities	-2,205
Cash Flows from Financing Activities:
Proceeds from issuance of note payable	949,000
Repayments of notes payable
Proceeds from sale of assets
Related party advances	-88,321	175,182
Net Cash Provided (Used) by Financing Activities	860,679	175,182
Net increase/decrease in Cash	148,794	-244,637
Cash at beginning of period	2,000	244,637
Cash at end of period	150,794
Supplemental cash flow information:
Interest paid	0
Taxes paid	$0

History_of_the_Company_and_Nat

History of the Company and Nature of the Business	9 Months Ended
	Dec. 31, 2014
History Of Company And Nature Of Business [Abstract]
History of the Company and Nature of the Business	1. History of the Company and Nature of the Business
	“We”, “us” and “our” refer to FutureWorld Corp., a Delaware corporation.
	On June 11, 2014, the Company changed its name to FutureWorld Corp.
	Nature of Business
	The address of our executive offices is: 3637 4th Street North, Saint Petersburg, FL 33704 and our telephone number at that address is 427-474-1816. The address of our web site is www.futureworldcorp.com. The information at our web site is for general information and marketing purposes and is not part of this quarterly report for purposes of liability for disclosures under the federal securities laws.
	FutureWorld Corp., a Delaware corporation, is a U.S. diversified Industrial Hemp/ Medical Cannabis Company, which together with its subsidiaries, focuses on the identification, acquisition, development, and commercialization of Hemp/Cannabis products, services and technologies globally under the banner of Cannabis 2.0.
	We are seeking to acquire minority or full interest in currently operating companies and disruptive technologies in the Industrial Hemp/Medical and Recreational Cannabis Industry globally; such as vaporizers, lab testing, tracking systems, security, Cannabidiol (CBD) oil, testing kits, financial solutions, dispensaries and other needed components. Our goal is to provide our acquired companies, current and future shareholders a clear strategy for the growth of their companies and their investment in those companies.
	We currently provide multiple products that supply the burgeoning cannabis industry. The “picks and shovel” business model capitalizes of selling enterprises associated with the Industrial Hemp and Medical Cannabis industries products that are essential in their success. Our products solve long standing problems in cultivation, processing, and retail sales for industrial hemp and medical cannabis. The following divisions will continue to delve even further into purchasing existing products or developing brand new products as the wholesale and retail space continues to evolve. In addition, one primary focus is to manufacture, market, and sell products containing hemp derived CBD oil. We are invested in the following portfolio companies as subsidiaries;
	NutraCann Labs Inc.
	CBD Oil- CBD is one of at least 60 cannabinoids found in hemp, and is non-psychoactive. The Cannabidiol “CBD” is a compound in cannabis that has significant medical effects, but does not make people feel “high” and can actually counter the psychoactive effects of THC. The reduced psychotropic of CBD-rich cannabis makes it an appealing treatment option for patients seeking anti-inflammatory, anti-pain, anti-anxiety, anti-psychotic, and/or anti-spasm effects without disconcerting lethargy. Scientific and clinical studies underscore CBD’s potential as a treatment for a wide range of conditions, including rheumatoid arthritis, diabetes, alcoholism, MS, chronic pain, schizophrenia, PTSD, antibiotic-resistant infections, epilepsy, and other neurological disorders. CBD has demonstrated neuro-protective and neurogenic effects, and its anti-cancer properties are currently being investigated at several academic research centers in the United States and elsewhere.
	The present usage for CBD oil in the United States is estimated to be approximately 1,000-2,000 Kilograms a year and growing and with a yearly value of around $200,000,000. Currently, the apparent current competitors are; CannaVest, Inc. and Medical Marijuana, Inc., which own portions of each other’s companies, are the primary supplier of CBD oil in the United States. They supply the product in bulk to affiliate distributors and sell it retail in plastic tubes that are refined up to three levels. Real Scientific Hemp Oil™ is their trademark name.
	NutraCann Labs has sourced its own CBD oil from Europe. We are also developing plans to fund an overseas hemp cultivation project to provide a consistent and reliable supply to the United States and beyond. Currently, industrial hemp cultivation is legal in twenty countries around the world. NutraCann’s products are sold under the brand name “cbdessence” on CBDESSENCE.COM.
	NutraCann Labs will process the CBD oils that will be sold through our online presence for retailing industrial hemp oil-based Cannabidiol (CBD) nutritional supplements, wellness and personal care products and vapable CBD oils. NutraCann Labs will market items such as CBD oil, CBD infused edibles & multiple hemp related items and cross market our vaporizers from URVape.com. NutraCann Labs will be featuring scientific grade hemp oil which is highly sought after around the world. We will sell already recognizable brands including our own brands and drive internet sales through ads, videos, social media and Search Engine Optimization.
	The global Nutraceutical market is projected to be in excess of $200 billion by 2015 and the current US Nutraceutical and Dietary supplement market is valued at around $42 billion. CBDESSENCE.com and URCBDOil.com will be at the forefront of this massive marketplace with significant opportunities. Cannabinoids (non-psychoactive CBD) have been found to have antioxidant properties, unrelated to NMDA receptor antagonism. This new found property makes cannabinoids useful in the treatment and prophylaxis of a wide variety of oxidation associated diseases, such as ischemic, age-related, inflammatory and auto-immune diseases.
	Cannabinoids are found to have particular application as neuroprotectants, for example in limiting neurological damage following ischemic events, such as stroke and trauma, or in the treatment of neurodegenerative diseases, such as Alzheimer's, Parkinson's and HIV dementia. URCBDOil.com should be live by July 1, 2014 UPDATE). CBDESSENCE.com and URCBDOil.com will assist FutureWorld to generate positive cash flow for both URVape and our CBD oil and CBD infused products offered by NutraCann Labs.
	CB Scientific, Inc.
	CB Scientific, Inc. a wholly owned subsidiary based in Denver Colorado has developed new technologies specifically for cannabis analytics. Charles Steinburg, President of Herbal Synergy and Acting Vice President of CB Scientific Division, has been one of the main men behind gas chromatography testing in Colorado. Charles Steinberg’s credentials will prove to be an asset to CB Scientific He has been a judge at several High Times Cannabis Cups. CB Scientific introduced the first ever personal cannabinoid detection kits. These kits test all your products in-house and at your own convenience. These tests are quick, easy, and effective. CB Scientific’s new PERSONALANALYTICS THC & CBD detection kit is the first simple, quick and accurate consumer THC & CBD test which will give you’re an accurate reading of THC or CBD in any product you purchase, manufacture, or grow While many medical and recreational products are sold with cannabinoid levels listed, these numbers are often not representative of what is being sold.
	URVape, Inc.
	URVape™ is our brand name vaporizer pen which is sold with a charger and refill bottles. We market the product at URVape.com. It is our own trademarked vaporizer being marketed and sold online and in retail shops. The product is cutting edge design and requires puffing on the pen to facilitate battery use. The URVape vaporizing pen is sleek and lightweight. URVape will initially have oil vaporizers available and dry herb versions available in the coming months.
	URVape was started to contribute to the current revolution, which has become an international phenomenon, known as the "Vaping" industry. URVape began test marketing OEM branded, off-the-shelf oil vaporizers, whose design and utility was well received, and which promulgated our first vendor agreement in the state of Colorado.
	After studying the marketplace, with more than 466 vendors attempting to reach nicotine consumers, we recognized early on that there were unsupported claims and deficiencies in the products and e-liquids being sold. Product deficiencies were noted in the devices being used in combination with e-liquids, which, together could be producing harmful elements. Consequently, these elements are being inhaled as a result of heating the contents of the e-liquids, thereby producing potentially harmful changes to the initial ingredients. As a result, URVape has dedicated itself to providing products that are free of any substances which, when heated for vaping, could be harmful.
	URVape has entered into an exclusive Non-disclosure/Non-compete contract with one of the foremost international vaping products manufacturers. Through our in-house Product Development personnel, and through the hiring of a consultant whose area of expertise is microbiology, specific to cannabis and vaping, we have developed two primary device changes that are being patented. These changes are designed to produce safe devices, built with safe materials, and to exact temperature specifications suited to a variety of e-liquids that we will bring to market.
	We are also developing new methods of producing, packaging and flavoring a variety of e-liquids with the intention to provide consumers with happy, healthy and potentially curative products.
	URVape’s plans include the installation of its own laboratory along with a "clean room" for production of its products. The goal is to become the market leader of safe vaping materials. To that end, URVape has Trademarked "SafeVape" for use in describing the technologies utilized in bringing both devices and e-liquids to the marketplace.
	The E-cigarette, Cannabis and Herbal vaping industry is an ever growing and evolving industry. Business models need to be constantly adjusted and configured based on all moving parts. But we are fortunate to be part of this historical moment in time where consumers around the globe will finally have access to natural plant derivatives to enhance their health and enjoyment without the inherent side effects of synthetic medicines. URVape will be part of that historical moment creating technologies for the delivery of its specialized, researched products. With the decriminalization and legalization of cannabis for medicinal and recreational use in many states and countries throughout the world the adoption of electronic vaporizing by the world’s 1.2 Billion smokers - eCig or vaporizer market is the fastest market within the tobacco (free) industry and estimated to be a multi-billion dollar industry within a few years.
	HempTech Corp:
	HempTech Corp has several products available specifically geared to helping cultivators of industrial hemp and medical cannabis maximum yields while helping to control costs. CaNNaLyTiX™ , SPIDer™, SmartSense™ ,Smart.NRG™ , and CaNNaTRAK™.
	CaNNaLyTiX™ “A picture is worth a thousand words” and being able to visualize all the various aspects of a cultivation enterprise solves challenges before they become problems. CaNNaLyTiX™ is a dashboard controller system that allows the various computer systems to be integrated throughout a cultivator’s infrastructures. Using state-of –the-art API connecting software packages, CaNNaLyTiX™ can allow all computer systems to be monitored with the ease of a smartphone app and the robust hardware of integrated servers or cloud-based application.
	CaNNaTRAK™- the next generation of barcode & RFID tracking systems for keeping pace with the extensive demands of seed to sale tracking of Hemp/Cannabis for state compliance. We are currently developing “game changer” modifications that will make it the ultimate software system in the industry. CannaTRAK’s Asset Tracking Management Software automates the major aspects of the Asset Life Cycle. The Product suite is made up of modules, which are able to operate independently of one another, are able to be configured to work together, or to be integrated with non-native applications. CaNNaTRAK™ software easily tracks assets using bar coding, radio frequency (RFID), imaging, and wireless technologies. CaNNaTRAK™ software is designed under the client/server architecture, is multi-user and menu-driven following industry-standard MS Windows protocols and graphical user interfaces. CaNNaTRAK™ applications are compatible with MS Windows XP, Vista, Windows 7 & 8.1 operating systems and with SQL Server 2008 through 2013.
	CaNNaTRAK’s mobile information applications are compatible with Windows Mobile devices and are tightly integrated with; bar coding, RFID, GPS, imaging, biometrics and wireless technologies. Due to the State law, legal governance, compliance and tax reasons, we believe CaNNaTRAK™ will be an invaluable tool for legal compliance and profitability from growers to dispensers of the legal medicinal marijuana. Over the past decade, 22 (any change since November elections?)states have approved the use of medicinal marijuana. Medicinal marijuana has become an alternative to traditional treatments for patients with clinical diseases such as cancer and HIV/AIDS. The medicinal marijuana market is estimated to be valued in the billions of dollars initially and may provide hundreds of millions of dollars tax revenue for the state’s tax coffers.
	We believe compliance and governance will be a big concern for the state offices overseeing the cannabis lifecycle and CaNNaTRAK™ will be an invaluable tool to comply and monitor for the medicinal marijuana industry. Our competition presently consists of the MITS system being used in the state of Colorado, the BioTrackTHC system being used in the state of Washington, and MJ Freeway. Certainly we will look to enter every burgeoning market throughout the United States.
	SPIDer (Secure Perimeter Intrusion Detection Network) is a system to meet the needs of theft and malicious attacks. While the economy is seeing improvement, theft, site destruction, and malicious activity are still happening at an alarming rate and within the legal Cannabis/Hemp industry surging forward we can expect no change particularly because of its specific draw. The SPIDer systems consist of 3 levels of detection to identify intruders and threats in areas that are restricted.
	The first level utilizes an electronically charged coaxial cable woven into your chain link fencing. Excessive fence movement will set off an alarm through your network notification system that someone is attempting to enter your facility. This is a very cost effective means to secure your site to meet security requirements for your company. The second level consists of a visual intrusion monitoring system. It is a wireless, battery operated, and connected through the cellular network. It provides 24/7 monitoring and notification through the internet and email system. Once an intruder is identified an alarm is sent to the security team with a picture that allows you to identify if this is an authorized or unauthorized person.
	The network system can quickly be deployed and moved to provide security coverage as needed. The third level is a multi-level detection and verification system that uses both level one and level two to rapidly identify a potential intruder and provide you information for a rapid decision. The combination of the two systems provides the additional barriers for quick action. Sometimes seconds are critical in preventing serious damage or theft at your site. The command center software provides intrusion notification to your network center and to individuals via email. For level two and three you receive a picture that enables you to make a more informed and quicker decision concerning your action.
	The SPIDer solution addresses the potential threat facing the entire Cannabis/Hemp industry. With this system you are able to supply your security team with information that enables them to be proactive in addressing these costly activities. Compliance with state rules and regulations for the Cannabis/ Hemp industry is going to be essential. Though there are many security companies on the market, few are adapting themselves to the Cannabis industry.
	SmartSense- offers wireless security and smart sensor mesh network for precision agriculture, irrigation systems, and greenhouses for the hemp industry. Our Smart Agriculture models allow monitoring multiple environmental parameters involving a wide range of applications with smart sensors such as Leaf Wetness, Atmospheric Pressure, Solar Radiation, Air Temperature / Humidity, Soil Temperature / Moisture, Ultraviolet Radiation etc. The smart sensor information will be collected and sent via the cloud to the central office for analysis and procedural modifications. FutureWorld is not aware of any another competitor in the United States. FutureWorld, through HempTech plans on marketing the product to large and medium sized grow facilities since they will have the greatest need.
	SmartNergy- offers tools to analyze every aspect of a cultivator’s energy usage. Being fully integrated with CaNNaLyTiX™, one can visualize energy consumption in real-time and track historical usage. The software’s predictive functionality also helps optimize energy use challenges proactively. We believe a cultivator’s huge electric bills can be scaled back when the entire grow is looked at as a complete and fully integrated operation.
	CaNNaBoX™- Much like a bank ATM, the CaNNaBoX™ machine operates with the swipe of a card, which will verify identity, age and prescription information of a medical marijuana patient before releasing measured packages of marijuana. The advantage is you will not have to be waited on by an assistant if you don't require consultation and the store location is busy. The machine is capable of holding several hundred items in multiple forms of marijuana. CaNNaBoX™ is a secure robotic device specifically designed for dispensing cannabis products in secure prepackaged amounts, in complete accordance with state law requirements, in licensed dispensaries, and only to legal buyers.
	FutureWorld has teamed up with American Green to brand the Zazzz Dispensary machine with the CaNNaBoX™ logo and distribute the product across the United States and possibly worldwide. Presently the Zazzz machine presented by American Green, which is first to the market, MedBox Inc.’s machine, and a vending machine product by Endexx Corp also distribute the product. The model for FutureWorld is to bring 1500 units to market within a couple years in accordance with our JV goals alongside American Green and its Zazzz machine.
	There will be a revenue sharing agreement with American Green and FutureWorld for every placed CaNNaBoX™ machine via monthly leasing and transaction costs. We are currently putting together the details of the JV with American Green and beginning the marketing and design phase of our product. Revenues are purely a function of quantity at this point. A monthly leasing fee of approximately $150 dollars a month and a transaction cost somewhere between $1.50 and $2.00 per. Competing brands are to look for a large upfront expenditures from dispensaries for the machines which we believe will make their sales model harder to actual achieve sales nationwide.
	CaNNaBoX™ will be marketed exclusively through our new dispensary division, DispenseTek. DispenseTek was created to market and sell dispensary related products and services including but not limited to CaNNaBoX™. It is important to understand, CaNNaBoX™ robotic dispensaries are secure delivery and control systems for use in licensed cannabis dispensaries and not “vending machines”. Their specific design benefits public safety, governance, dispensaries, and consumers.
	HempTech has also signed an agreement with Colorado Flower Company to provide turnkey state-of-the-art technology for their grow facility which is being built on our land in Colorado. The contract calls for $1.5M and the technology is leased at $190K per month for five years.
	FutureLand Properties, LLC.
	On October 06, 2014, the Company has formed a 100% owned subsidiary: Futureland Properties, LLC in the state of Colorado. FutureLand’ s primary purpose is to purchase properties for lease back or lease to Hemp farmers and medical cannabis growers. Futureland Properties purchased a 240 acres of agricultural land in the southern Colorado. FutureLand Properties, LLC, closed on 237 acres in southern Colorado on October 30th, 2014 for the purpose of leasing to licensed Cannabis and Hemp growers. The decision was made based on increased demand for medical and recreational cannabis and loosening of some restrictions in Colorado. We believe the future of cannabis grows will belong to large state-of-the-art facilities much like agricultural industry. In Colorado and other legal states, only few large cannabis grow facilities will remain which would allow for easier supervision and administration by the State and Federal government.
	On December 5, 2014, the Company announces the completion of a Commercial Lease Agreement effective 1st day of December, 2014 by and between FutureLand Properties, LLC, a Colorado corporation ("Landlord") and Colorado Flower Company, LTD. ("Tenant"). FutureLand is the owner of land and improvements commonly known as TWP 27 RNG 68 SEC 25: NE4NW4 LESS 3 ACRES FOR RIGHT OF WAY TOTAL ACRES 37, La Vita Colorado 81011 (hereinafter the "Property"). FutureLand will be the owner of a 14,940 square foot greenhouse and any other structures to be constructed/situated on the Property. The greenhouse and land may be collectively referred to hereinafter as the "Leased Premises.". This Commercial Lease Agreement is for five (5) years and FutureLand shall also grant to the Tenant additional three (3) years options to renew this Commercial Lease at Tenant's sole discretion.
	The Company is to finance and build 2000+ plant cannabis cultivation greenhouse for Colorado Flower Company on a 37 acres property owned by the Company. This large cultivation facility will be one of many on the same property. Company is also to provide high tech automation solutions to control all processes in the greenhouses based on HempTech's state-of-the-art technologies.
	The Company (through separate agreements with HempTech and CB Scientific) will provide greenhouse, processing equipment, Spider Security Technology, SmartSense, SmartNergy, CaNNaLyTiX, and growing/laboratory equipment located on the Property provided by HempTech Corp and CB Scientific. HempTech Corp., a FutureWorld Corp. subsidiary, will supply Spider Security Technology, SmartSense, SmartNergy and CaNNaLyTiX. CB Scientific, a FutureWorld Corp. subsidiary, will supply all testing and laboratory equipment to the Grow.
	The master lease agreement calls for $575,000 monthly lease payments for the land, the greenhouse and the technology for five years.
	FutureLand Properties only leases the land, infrastructure and technologies. It does not grow or sell or distribute any products that are in violation of the United States Controlled Substances Act (US.CSA).

Basis_of_Presentation_Business

Basis of Presentation, Business and Summary of Significant Accounting Policies	9 Months Ended
	Dec. 31, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation, Business and Summary of Significant Accounting Policies	2.   Basis of Presentation, Business and Summary of Significant Accounting Policies
	Basis of Presentation
	In the opinion of management, all adjustments consisting of normal recurring adjustments necessary for a fair presentation of (a) the results of operations for the three and six months ended December 31, 2014 and 2013: (b) the financial position at December 31, 2014 and March 31, 2014 and (c) cash flows for the three and nine months ended December 31, 2014 and 2013, have been made. Management believes that these estimates are reasonable and have been discussed with the Board of Directors; however, actual results could differ from those estimates.
	The accompanying unaudited financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and in accordance with the instructions to Form 10-Q and Article 8 of Regulation S-X. Accordingly, they do not included all of the information and footnotes required by accounting principles generally accepted in the United States of America for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. For further information regarding the Company’s significant accounting policies, refer to the audited consolidated financial statements and footnotes thereto included in the Company’s Annual Report on from 10-K for the year ended March 31, 2014 filed with the Securities and Exchange Commission on October 31, 2014.
	Our financial statements may not be comparable to companies that comply with public company effective dates. Due to our election not to opt out of the extended transition period that allows us to delay the adoption of new or revised accounting standards that have different effective dates for public and private companies until those standards apply to private companies. All amounts referenced in these Financial Statements and this Report are in US Dollars unless otherwise stated.
	Nature of the Business, and History of the Company and its Subsidiaries
	The nature of the business and the history of the Company and its subsidiaries are as follows:
	Nature of the Business
	FutureWorld Corp., a Delaware corporation, is a U.S. diversified Hemp/Cannabis Company, listed on the Over the Counter exchange, which was originally formed to capitalize on the burgeoning markets in renewable and alternative energy technologies, but has since changed direction and moved into the Hemp/Cannabis space. FutureWorld, together with its subsidiaries, focuses on the identification, acquisition, development, and commercialization of Hemp/Cannabis products, services and technologies globally.
	FutureWorld is seeking to acquire minority or full interest in currently operating companies and disruptive technologies in the Industrial Hemp/Medical and Recreational Cannabis Industry globally; such as vaporizers, lab testing, tracking systems, security, CBD oil, testing kits, financial solutions, dispensaries and other needed components. Our goal is to provide our acquired companies, current and future shareholders a clear strategy for the growth of their companies and their investment in those companies.
	Principles of Consolidation
	The consolidated financial statements include the accounts and operations of FutureWorld Corp., and its wholly owned subsidiaries, URVape, Inc., HempTech Corp., CB Scientific, FutureLand Properties, LLC and MedTest Inc.
	Basis of Accounting
	The Company maintains its financial records and financial statements on the accrual basis of accounting, in conformity with generally accepted accounting principles in the United States of America. The accrual basis of accounting provides for matching of revenues and expenses in the period they were earned and incurred.
	Cash and Cash Equivalents
	For purposes of reporting cash flows, the Company considers all cash accounts that are not subject to withdrawal restrictions or designated for assets acquisitions, and certificates of deposit that have an original maturity of three months or less when purchased, to be cash equivalents. The Company believes it is not exposed to any significant credit risk on cash and cash equivalents.
	Fair Value of Financial Instruments
	The following methods and assumptions were used by the Company in estimating its fair value disclosures for financial instruments:
		•	Cash and Cash Equivalents, Accounts Receivable, Prepaid Expenses, Accounts Payable,  and  Accrued Expenses :
			The carrying amount reported in the balance sheets for these items approximates fair value because of the short maturity of these instruments.
		•	Loans and Notes Payable to Related Parties:
			The carrying value of loans and notes payable to related parties approximates fair value as each of the notes payable carries an interest rate commensurate with commercial borrowing rates available to the Company.
			As of December 31, 2014 and March 31, 2014, the fair values of the Company’s financial instruments approximate their historical carrying amount.
	Accounts Receivable
	Accounts receivable consist of amounts due for the delivery of Product sales to customers. An allowance for doubtful accounts is considered to be established for any amounts that may not be recoverable, which is based on an analysis of the Company’s customer credit worthiness, and current economic trends. Based on management’s review of accounts receivable, no allowance for doubtful accounts was considered necessary as of period end. Receivables are determined to be past due, based on payment terms of original invoices. The Company does not typically charge interest on past due receivables. Balances on Current sales are due in 60 days from the date of sale.
	Inventory
	Inventory consists of finished product, URVape electronic vaporizing cigarettes valued at the lower of cost or market valuation under the first-in, first-out method of costing, PersonalAnalytics testing kits that are also valued at the lower of cost or market valuation under the first-in, first-out method of costing and CBD bulk oil that are also valued at the lower of cost or market valuation under the first-in, first-out method of costing.
	Property and Equipment
	Property and equipment are recorded at historical cost.  Depreciation is computed on the straight-line method over estimated useful lives of the respective assets, ranging from three to seven years.  The carrying amount of all long-lived assets is evaluated periodically to determine if adjustment to the depreciation periods or the unamortized balance is warranted.  Based upon the Company's most recent analysis, management believes that no impairment of property and equipment exists at December 31, 2014 and March 31, 2014.
	Intangible assets
	Intangible assets are recorded at cost and amortized over their useful lives. The Company's goodwill associated with its acquisitions is not amortized. Management reviews goodwill for impairment at least on an annual basis and at other times when existing conditions raise substantial questions about their recoverability.
	Impairment of Long-Lived Assets
	Periodically, the Company assesses the recoverability of the Company’s intangible assets, consisting of the Intellectual Property & licensing for CaNNaTRAK, SmartSense, CaNNaLyTiX and its trademark, and record an impairment loss to the extent that the carrying amounts of the assets exceed its fair value.  Based upon management's most recent analysis, the Company believes that no impairment of the Company’s tangible or intangible assets exist at December 31, 2014 and March 31, 2014.
	Revenue Recognition
	The Company is principally in the business of providing solutions to the cannabis industry that incorporates our CaNNaTRAK, SmartSense, URVape, PersonalAnalytics and CaNNaLyTiX technologies. Contracts include multiple revenue components, comprised of our product sale, software licensing, hardware platforms, installation, training and maintenance.  In accordance with ASC 605-25 Multiple-Element Arrangements, revenue from licensing the software will be recognized upon installation and acceptance of the software by customers. Revenue from sale of products (URVape & PersonalAnalytics) will be recognized upon the delivery of the product to our customer. When a software sales arrangement includes rights to customer support, the portion of the license fee allocated to such support is recognized ratably over the term of the arrangement, normally one year.  Revenue from professional services arrangements will be recognized in the month in which services are rendered over the term of the arrangement.
	Revenue associated with software sales to distributors is recognized, net of discounts, when the Company has performed substantially all its obligations under the arrangement.  Until such time as substantially all obligations under the arrangement are met, software sales are recognized as deferred revenue.  Costs and expenses associated with deferred revenue are also deferred.  When a software sales arrangements include a commitment to provide training and/or other services or materials, the Company estimates and records the expected costs of these training and/or other services and/or materials.
	Foreign currency translation
	The Company’s functional currency and its reporting currency is the United States Dollar.
	Cost of Goods Sold
	The Company recognizes the direct cost of purchasing product for sale, including freight-in and packaging, as cost of goods sold in the accompanying income statement.
	Stock Based Compensation
	The Companies estimate the fair value of share-based payment awards to employees and directors on the date of grant using an option-pricing model. For stock-based awards issued to employees and directors, stock-based compensation is attributed to expense using the straight-line single option method, which is consistent with how the prior-period pro-forma were provided. Stock-based compensation expense recognized in the Statements of Operations for the three and nine months ended December 31, 2014 and 2013 included compensation expense for share-based payment awards granted prior to, but not yet vested based on the grant date fair value estimated and compensation expense for the share-based payment awards granted subsequent to January 1, 2013 based on the grant date fair value estimated.
	The Company’s determination of fair value of share-based payment awards to employees and directors on the date of grant using the Black-Scholes model, which is affected by the Company’s stock price as well as assumptions regarding a number of highly complex and subjective variables. These variables include, but are not limited to our expected stock price volatility over the term of the awards, and actual and projected employee stock option exercise behaviors.
	Income Taxes
	The Company records federal and state income tax liability at the federal and state rates after allowances. Deferred income taxes are provided on the liability method whereby deferred tax assets are recognized for deductible temporary differences and operating loss and tax credit carry forwards, and deferred tax liabilities are recognized for taxable temporary differences. Temporary differences are the differences between the reported amounts of assets and liabilities and their tax bases.
	Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment.
	Tax benefit from an uncertain tax position may be recognized in the financial statements when it is more likely than not that the position will be sustained upon examination, including resolutions of any related appeals or litigation processes, based on the technical merits. Income tax positions must meet a more-likely-than-not recognition threshold at the effective date to be recognized and in subsequent periods.
	The Company adopted a policy under which, if required to be recognized in the future, they will classify interest related to the underpayment of income taxes as a component of interest expense and will classify any related penalties in selling, engineering, general and administrating expenses in the statement of operations.
	Advertising Costs
	Advertising costs are charged to operations as incurred.
	Earnings (Loss) Per Share
	Basic EPS is calculated by dividing earnings (loss) available to common shareholders by the weighted average number of common shares outstanding during each period.  Diluted EPS is similarly calculated, except that the denominator includes common shares that may be issued subject to existing rights with dilutive potential, except when their inclusion would be anti-dilutive.
	Based on an estimated current value of the Company’s stock being equal to or less than the exercise price of the warrants, none of the shares assumed issued upon conversion of the warrants, nor any of the stock assumed issued under the Company's Incentive Stock Plan are included in the computation of fully diluted loss per share, since their inclusion would be anti-dilutive.
	Impact of Recently Issued Accounting Pronouncements
	In April 2014, the FASB issued ASU 2014-08, Presentation of Financial Statements and Property, Plant, and Equipment. ASU No. 2014-08 defines a discontinued operation as disposal of components of an entity that represents a strategic shift that has or will have a major effect on an entity’s operations. ASU No. 201408 also requires a reporting entity to present the assets and liabilities of a disposal group that includes a discontinued operation separately in the asset and liability sections, respectively, of the statement of financial position for each comparative period. ASU 2014-08 becomes effective for interim and annual periods beginning on or after December 15, 2014. Adoption of ASU 2014-08 is not expected to have a significant impact on the Company’s consolidated financial statements.
	In August 2014, the FASB issued ASU 2014-15, Presentation of Financial Statements-Going Concern. This statement provides US GAAP guidance on management’s responsibility in evaluation whether there is substantial doubt about a company’s ability to continue as a going concern and about related footnote disclosures. For each reporting period, management will be required to evaluate whether there are conditions or events that raise substantial doubt about a company’s ability to continue as a going concern within one year from the date the financial statements are issued. The ASU is effective for annual periods ending after December 15, 2016 and interim periods thereafter.
	In November 2014, the FASB issued ASU 2014-16-Derivatives and Hedging: Determining Whether the Host contract in a Hybrid Financial Instrument issued in the Form of a Share is More Akin to Debt or to Equity. Certain classes of shares include features that entitle the holders to preferences and rights (such as conversion rights, redemption rights, voting powers and liquidation and dividend payment preferences) over the other shareholders. Shares that include embedded derivative features are referred to as hybrid financial instruments, which must be separated from the host contract and accounted for as a derivative if certain criteria are met. This ASU is effective for fiscal years and interim periods within those fiscal years beginning after December 15, 2015
	Other recent accounting pronouncements issued by the FASB, the American Institute of Certified Public Accountants, and the Securities and Exchange Commission did not or are not believed by management to have a material impact on the Company's present or future financial statements.

Going_Concern

Going Concern	9 Months Ended
	Dec. 31, 2014
Liquidity Disclosure [Abstract]
Going Concern	3.  Going Concern
	For the quarter ended December 31, 2014, the Company incurred a net loss of $167,793 and a cumulative net loss since inception of $648,546.  As of December 31, 2014, the Company had cash of $150,794 and working capital deficit of $1,099,308 with which to satisfy any future cash requirements.  These conditions raise substantial doubt about the Company's ability to continue as a going concern.  The Company depends upon capital derived from future financing activities such as loans from its officers and directors, subsequent offerings of its common stock or debt financing in order to operate and grow the business either directly or through its subsidiary.  There can be no assurance that the Company will be successful in raising such capital.  The key factors that are not in the Company's control and that may have a direct bearing on operating results.  These factors include, but are not limited to, acceptance of the Company’s business plan, the ability to raise capital in the future, the ability to expand its customer base, and the ability to hire key employees to grow the business.  There may be other risks and circumstances that management may be unable to predict.

Property_and_Equipment

Property and Equipment	9 Months Ended
	Dec. 31, 2014
Property, Plant and Equipment [Abstract]
Property and Equipment	4.  Property and Equipment
	Property and equipment as of December 31, 2014 and March 31, 2014 consists of the following:
		31-Dec-14		Mar-14
	Computer equipment	$	1539-	$	-
	Furniture and fixtures		0-		-
			-		-
	Accumulated depreciation		565-		-
	Net	$	974-	$	-

Intangibles

Intangibles	9 Months Ended
	Dec. 31, 2014
Goodwill and Intangible Assets Disclosure [Abstract]
Intangibles	5.   Intangibles
	On May 2, 2014, the Company acquired the assets of MedTest, Inc., including Product Technology for 5,000,000 shares of Common Stock valued at $100,000.  FutureWorld also acquired certain Trademarks from HempTech Corp., URVape, Inc., and CB Scientific, Inc. for in April of 2014 valued at $825. The useful lives of the Product Technology and Trademarks have been evaluated to have a useful life of 15 years and are being amortized accordingly per the financial statements. For the three and nine months ended December 31, 2014, the amortization expense for intangible assets was $6,726 and $9,531, respectively.
		31-Dec-14		31-Mar-14
	HempTech Product Technology	$	100,000	$	-
	Trademarks		825		-
			-		-
	Accumulated Amortization		-9,531		-
	Intangibles, Net	$	91,294	$	-

Stock_Options_and_Awards

Stock Options and Awards	9 Months Ended
	Dec. 31, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock Options and Awards	6.     Stock Options and Awards
	The company currently has agreements with certain employees that offer stock options and stock awards. The company is valuing stock options and stock awards using Black-Scholes and currently amortizing over the vesting periods. For the three and nine months ended December 31, 2014 the company has amortized $27xxx and $22xxx, respectively. Options and Shares are expected to vest in accordance with the following schedule:
						Weighted Average				Remaining
		Options		Options		Intrinsic		Exercise		Contractual
		Outstanding		Vested		Value		Price		Term
	Options, March 31, 2014		0		0
	Granted		8,350,000		37,500		$0		$ 0.0262	3.46 yrs
			0		0
	Forfeited		0
	Options, December 31, 2014		8,350,000		37,500
	Option Expense for the three and nine months ended was $17,951 and $33,235, respectively.
		Awards		Awards
		Outstanding		Vested
	Options, March 31, 2014		0		0
	Granted		4,600,000		0
	Exercised		0		0
	Forfeited		0		0
	Options, December 31, 2014		4,600,000		0
	Stock Awards Expense for the three and nine months ended was $8,164 and $15,778, respectively.

Accrued_Expenses

Accrued Expenses	9 Months Ended
	Dec. 31, 2014
Accrued Liabilities, Current [Abstract]
Accrued Expenses	7.  Accrued Expenses
	Accrued expenses at December 31, 2014 and March 31, 2014 were as follows:
		31-Dec-14		31-Mar-14
	Accrued salaries and payroll taxes	$	1,154,172	$	1,030,071
	Accrued interest		138,609		594,590
	Accrued penalties				-
		$	1,292,781	$	1,089,530

Related_Parties_Disclosures

Related Parties Disclosures	9 Months Ended
	Dec. 31, 2014
Related Party Transactions [Abstract]
Related Parties Disclosures	8.   Related Parties Disclosures
	Loan from Saeed (Sam) Talari
	Mr. Talari has advanced funds to the Company at various times. On April 1, 2010 the Company issued a promissory note with an initial balance of $306,319 bearing interest at 5%. This note allows Mr. Talari to advance additional funds to the Company as needed. At December 31, 2014 and March 31, 2014, the balance due to Mr. Talari on this Promissory Note is $205,748 and $299,118 respectively, and the accrued interest thereon at December 31, 2014 and March 31, 2014 is $67,511 and $45,048 respectively.

Employment_Agreements

Employment Agreements	9 Months Ended
	Dec. 31, 2014
Employment Agreements [Abstract]
Employment Agreements	9. Employment Agreements
	Sam Talari
	On January 1, 2012, the Company entered into a three-year Employment Agreement with Mr. Talari, the Company’s Acting Chief Executive Officer, and one of the Company's directors. The Agreement is automatically extended for additional one-year periods without further action from the Company or the executive, unless notice of termination is given by either party within 90 days of the end of any periods. The Agreement provides for (a) a base salary of $9,371 per month, with a 5% increase per annum and (b) all group insurance plans and other benefit plans and programs made available to the Company’s management employees. The balance of accrued salaries payable to Mr. Talari is $1,096,393 and $900,733 as of December 31, 2014 and 2013 respectively.
	Cameron Cox
	On April 15, 2014, the Company entered into a three-year Employment Agreement with Mr. Cox, the Company’s Acting Vice President of Business Development. The Agreement is automatically extended for additional one-year periods without further action from the Company or the executive, unless notice of termination is given by either party within 90 days of the end of any periods. The Agreement provides for (a) a base salary of $3,000 per month, with a 5% increase per annum, and (b) all group insurance plans and other benefit plans and programs made available to the Company’s management employees.
	Kevin Defant
	On April 21 2014, the Company entered into a three-year Employment Agreement with Mr. Defant, the Company’s Acting Tech Director. The Agreement is automatically extended for additional one-year periods without further action from the Company or the executive, unless notice of termination is given by either party within 90 days of the end of any periods. The Agreement provides for (a) a base salary of $2,000 per month, with a 5% increase per annum, and (b) all group insurance plans and other benefit plans and programs made available to the Company’s management employees.
	Bill Short
	On April 24, 2014, the Company entered into a three-year Employment Agreement with Mr. Short, CB Scientific’s Acting Chief Operations Officer. The Agreement is automatically extended for additional one-year periods without further action from the Company or the executive, unless notice of termination is given by either party within 90 days of the end of any periods. The Agreement provides for (a) a base salary of $3,000 per month, with a 5% increase per annum, and (b) all group insurance plans and other benefit plans and programs made available to the Company’s management employees
	Derek Lebahn
	On May 15, 2014, the Company entered into a three-year Employment Agreement with Mr. Lebahn, the Company’s Acting President of the CB Scientific Division. The Agreement is automatically extended for additional one-year periods without further action from the Company or the executive, unless notice of termination is given by either party within 90 days of the end of any periods. The Agreement provides for (a) a base salary of $2,000 per month, with a 5% increase per annum, and (b) all group insurance plans and other benefit plans and programs made available to the Company’s management employees.
	Charles Steinberg
	On May 15, 2014, the Company entered into a three-year Employment Agreement with Mr. Steinberg, the Company’s Acting Vice President of the CB Scientific Division. The Agreement is automatically extended for additional one-year periods without further action from the Company or the executive, unless notice of termination is given by either party within 90 days of the end of any periods. The Agreement provides for (a) a base salary of $2,000 per month, with a 5% increase per annum, and (b) all group insurance plans and other benefit plans and programs made available to the Company’s management employees.
	Joseph Kelly
	On June 18, 2014, the Company entered into a three-year Employment Agreement with Mr. Kelly, the Company’s Acting Product Development Executive for the CB Scientific Division. The Agreement is automatically extended for additional one-year periods without further action from the Company or the executive, unless notice of termination is given by either party within 90 days of the end of any periods. The Agreement provides for (a) a base salary of $1,600 per month, with a 5% increase per annum, and (b) all group insurance plans and other benefit plans and programs made available to the Company’s management employees.
	Andrew Marlatt
	On June 18, 2014, the Company entered into a three-year Employment Agreement with Mr. Marlatt, the Company’s Acting Product Development Executive for the CB Scientific Division. The Agreement is automatically extended for additional one-year periods without further action from the Company or the executive, unless notice of termination is given by either party within 90 days of the end of any periods. The Agreement provides for (a) a base salary of $2,000 per month, with a 5% increase per annum, and (b) all group insurance plans and other benefit plans and programs made available to the Company’s management employees.
	Richard Buck
	On June 18, 2014, the Company entered into a three-year Employment Agreement with Mr. Buck, the Company’s Acting Product Development Executive for the CB Scientific Division. The Agreement is automatically extended for additional one-year periods without further action from the Company or the executive, unless notice of termination is given by either party within 90 days of the end of any periods. The Agreement provides for (a) a base salary of $2,400 per month, with a 5% increase per annum, and (b) all group insurance plans and other benefit plans and programs made available to the Company’s management employees.

Office_Space

Office Space	9 Months Ended
	Dec. 31, 2014
Office Space [Abstract]
Office Space	10. Office Space
	During the Company's initial stage, it has limited need for use of office space or equipment.  The Company operates out of office space shared by the principals at an allocated cost of $ 1,440 per month.

Stockholders_Equity

Stockholders' Equity	9 Months Ended
	Dec. 31, 2014
Equity [Abstract]
Stockholders' Equity	11. Stockholders’ Equity
	Preferred Stock: The Company has 100,000,000 shares of $0.0001 par value stock Authorized. No shares have been issued or are outstanding as of December 31, 2014.
	Common Stock: The Company has 1,900,000,000 shares of $0.0001 par value stock Authorized. As of March 31, 2014, 446,373,966 shares were issued and outstanding.
	On May 2, 2014, 5,000,000 shares of stock were issued in accordance with a Share Exchange Agreement with MedTest, Inc. 1,500,000 shares were issued upfront for the share exchange and an additional 3,500,000 shares for certain benchmarks set for product pilots and development.
	On May 13, 2014, 1,000,000 shares of stock were issued in exchange for Services of $19,000.
	On August 29, 2014, 1,600,000 shares were issued in exchange for Services for $41,000
	As of December 31, 2014, there were 863,245,439 shares of common stock were issued and outstanding.

Subsequent_Events

Subsequent Events	9 Months Ended
	Dec. 31, 2014
Subsequent Events [Abstract]
Subsequent Events	11. Subsequent Events
	On January 20, 2015, the Company enters into a Commercial Lease Agreement between FutureLand Properties, LLC, a Colorado corporation ("Landlord") and GPS La Vita, Inc. ("Tenant"). FutureLand is the owner of the land LOT 19, PHASE 1, MAJORS RANCH, ACCORDING TO Plat Map No. 343, recorded April 30, 1995 in Pocket 7, Folder 3, Plat Map No. 351, recorded August 26, 1995 at Pocket 7, Folder 3, Plat Map No. 355, recorded September 29, 1995 at Pocket 7, Folder 3, Plat Map No. 392, recorded December 31, 1996 at Reception No. 327236, ACCORDING TO THE RECORDS OF THE CLERK AND RECORDER FOR HUERFANO COUNTY, COLORADO, La Vita Colorado 81011 (hereinafter the "Property"). FutureLand will lease out five (5) acres of the 200 Acres to GPS La Vita, Inc. The Commercial Lease Agreement is for five (5) years and FutureLand shall also grant to the Tenant additional (3) 5-year options to renew this Commercial Lease at Tenant's sole discretion. The Commercial Lease Agreement calls for $50,000 for leased Acres per month ($10,000 per Acre per month) for the term of the lease.
	The company will be obligated to buy back any and all improvements on the property within 36 months of operations at cost plus cumulative 10% cost of funds per annum. GPS shall have first right of refusal to participate in future grows on the property.
	The Company is in the process of selling all assets of HempTech to a public company. The company has also in the process of filing an S1 for URVape and CB Scientific.

Basis_of_Presentation_Business1

Basis of Presentation, Business and Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Dec. 31, 2014
Accounting Policies [Abstract]
Principles of Consolidation	Principles of Consolidation
	The consolidated financial statements include the accounts and operations of FutureWorld Corp., and its wholly owned subsidiaries, URVape, Inc., HempTech Corp., CB Scientific, FutureLand Properties, LLC and MedTest Inc.
Basis of Accounting	Basis of Accounting
	The Company maintains its financial records and financial statements on the accrual basis of accounting, in conformity with generally accepted accounting principles in the United States of America. The accrual basis of accounting provides for matching of revenues and expenses in the period they were earned and incurred.
Cash and Cash Equivalents	Cash and Cash Equivalents
	For purposes of reporting cash flows, the Company considers all cash accounts that are not subject to withdrawal restrictions or designated for assets acquisitions, and certificates of deposit that have an original maturity of three months or less when purchased, to be cash equivalents. The Company believes it is not exposed to any significant credit risk on cash and cash equivalents.
Fair Value of Financial Instruments	Fair Value of Financial Instruments
	The following methods and assumptions were used by the Company in estimating its fair value disclosures for financial instruments:
		•	Cash and Cash Equivalents, Accounts Receivable, Prepaid Expenses, Accounts Payable,  and  Accrued Expenses :
			The carrying amount reported in the balance sheets for these items approximates fair value because of the short maturity of these instruments.
		•	Loans and Notes Payable to Related Parties:
			The carrying value of loans and notes payable to related parties approximates fair value as each of the notes payable carries an interest rate commensurate with commercial borrowing rates available to the Company.
			As of December 31, 2014 and March 31, 2014, the fair values of the Company’s financial instruments approximate their historical carrying amount.
Accounts Receivable	Accounts Receivable
	Accounts receivable consist of amounts due for the delivery of Product sales to customers. An allowance for doubtful accounts is considered to be established for any amounts that may not be recoverable, which is based on an analysis of the Company’s customer credit worthiness, and current economic trends. Based on management’s review of accounts receivable, no allowance for doubtful accounts was considered necessary as of period end. Receivables are determined to be past due, based on payment terms of original invoices. The Company does not typically charge interest on past due receivables. Balances on Current sales are due in 60 days from the date of sale.
Inventory	Inventory
	Inventory consists of finished product, URVape electronic vaporizing cigarettes valued at the lower of cost or market valuation under the first-in, first-out method of costing, PersonalAnalytics testing kits that are also valued at the lower of cost or market valuation under the first-in, first-out method of costing and CBD bulk oil that are also valued at the lower of cost or market valuation under the first-in, first-out method of costing.
Property and Equipment	Property and Equipment
	Property and equipment are recorded at historical cost.  Depreciation is computed on the straight-line method over estimated useful lives of the respective assets, ranging from three to seven years.  The carrying amount of all long-lived assets is evaluated periodically to determine if adjustment to the depreciation periods or the unamortized balance is warranted.  Based upon the Company's most recent analysis, management believes that no impairment of property and equipment exists at December 31, 2014 and March 31, 2014.
Intangible assets	Intangible assets
	Intangible assets are recorded at cost and amortized over their useful lives. The Company's goodwill associated with its acquisitions is not amortized. Management reviews goodwill for impairment at least on an annual basis and at other times when existing conditions raise substantial questions about their recoverability.
Impairment of Long-Lived Assets	Impairment of Long-Lived Assets
	Periodically, the Company assesses the recoverability of the Company’s intangible assets, consisting of the Intellectual Property & licensing for CaNNaTRAK, SmartSense, CaNNaLyTiX and its trademark, and record an impairment loss to the extent that the carrying amounts of the assets exceed its fair value.  Based upon management's most recent analysis, the Company believes that no impairment of the Company’s tangible or intangible assets exist at December 31, 2014 and March 31, 2014.
Revenue Recognition	Revenue Recognition
	The Company is principally in the business of providing solutions to the cannabis industry that incorporates our CaNNaTRAK, SmartSense, URVape, PersonalAnalytics and CaNNaLyTiX technologies. Contracts include multiple revenue components, comprised of our product sale, software licensing, hardware platforms, installation, training and maintenance.  In accordance with ASC 605-25 Multiple-Element Arrangements, revenue from licensing the software will be recognized upon installation and acceptance of the software by customers. Revenue from sale of products (URVape & PersonalAnalytics) will be recognized upon the delivery of the product to our customer. When a software sales arrangement includes rights to customer support, the portion of the license fee allocated to such support is recognized ratably over the term of the arrangement, normally one year.  Revenue from professional services arrangements will be recognized in the month in which services are rendered over the term of the arrangement.
	Revenue associated with software sales to distributors is recognized, net of discounts, when the Company has performed substantially all its obligations under the arrangement.  Until such time as substantially all obligations under the arrangement are met, software sales are recognized as deferred revenue.  Costs and expenses associated with deferred revenue are also deferred.  When a software sales arrangements include a commitment to provide training and/or other services or materials, the Company estimates and records the expected costs of these training and/or other services and/or materials.
Foreign currency translation	Foreign currency translation
	The Company’s functional currency and its reporting currency is the United States Dollar.
Cost of Goods Sold	Cost of Goods Sold
	The Company recognizes the direct cost of purchasing product for sale, including freight-in and packaging, as cost of goods sold in the accompanying income statement.
Stock Based Compensation	Stock Based Compensation
	The Companies estimate the fair value of share-based payment awards to employees and directors on the date of grant using an option-pricing model. For stock-based awards issued to employees and directors, stock-based compensation is attributed to expense using the straight-line single option method, which is consistent with how the prior-period pro-forma were provided. Stock-based compensation expense recognized in the Statements of Operations for the three and nine months ended December 31, 2014 and 2013 included compensation expense for share-based payment awards granted prior to, but not yet vested based on the grant date fair value estimated and compensation expense for the share-based payment awards granted subsequent to January 1, 2013 based on the grant date fair value estimated.
	The Company’s determination of fair value of share-based payment awards to employees and directors on the date of grant using the Black-Scholes model, which is affected by the Company’s stock price as well as assumptions regarding a number of highly complex and subjective variables. These variables include, but are not limited to our expected stock price volatility over the term of the awards, and actual and projected employee stock option exercise behaviors.
Income Taxes	Income Taxes
	The Company records federal and state income tax liability at the federal and state rates after allowances. Deferred income taxes are provided on the liability method whereby deferred tax assets are recognized for deductible temporary differences and operating loss and tax credit carry forwards, and deferred tax liabilities are recognized for taxable temporary differences. Temporary differences are the differences between the reported amounts of assets and liabilities and their tax bases.
	Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment.
	Tax benefit from an uncertain tax position may be recognized in the financial statements when it is more likely than not that the position will be sustained upon examination, including resolutions of any related appeals or litigation processes, based on the technical merits. Income tax positions must meet a more-likely-than-not recognition threshold at the effective date to be recognized and in subsequent periods.
	The Company adopted a policy under which, if required to be recognized in the future, they will classify interest related to the underpayment of income taxes as a component of interest expense and will classify any related penalties in selling, engineering, general and administrating expenses in the statement of operations.
Advertising Costs	Advertising Costs
	Advertising costs are charged to operations as incurred.
Earnings (Loss) Per Share	Earnings (Loss) Per Share
	Basic EPS is calculated by dividing earnings (loss) available to common shareholders by the weighted average number of common shares outstanding during each period.  Diluted EPS is similarly calculated, except that the denominator includes common shares that may be issued subject to existing rights with dilutive potential, except when their inclusion would be anti-dilutive.
	Based on an estimated current value of the Company’s stock being equal to or less than the exercise price of the warrants, none of the shares assumed issued upon conversion of the warrants, nor any of the stock assumed issued under the Company's Incentive Stock Plan are included in the computation of fully diluted loss per share, since their inclusion would be anti-dilutive.
Impact of Recently Issued Accounting Pronouncements	Impact of Recently Issued Accounting Pronouncements
	In April 2014, the FASB issued ASU 2014-08, Presentation of Financial Statements and Property, Plant, and Equipment. ASU No. 2014-08 defines a discontinued operation as disposal of components of an entity that represents a strategic shift that has or will have a major effect on an entity’s operations. ASU No. 201408 also requires a reporting entity to present the assets and liabilities of a disposal group that includes a discontinued operation separately in the asset and liability sections, respectively, of the statement of financial position for each comparative period. ASU 2014-08 becomes effective for interim and annual periods beginning on or after December 15, 2014. Adoption of ASU 2014-08 is not expected to have a significant impact on the Company’s consolidated financial statements.
	In August 2014, the FASB issued ASU 2014-15, Presentation of Financial Statements-Going Concern. This statement provides US GAAP guidance on management’s responsibility in evaluation whether there is substantial doubt about a company’s ability to continue as a going concern and about related footnote disclosures. For each reporting period, management will be required to evaluate whether there are conditions or events that raise substantial doubt about a company’s ability to continue as a going concern within one year from the date the financial statements are issued. The ASU is effective for annual periods ending after December 15, 2016 and interim periods thereafter.
	In November 2014, the FASB issued ASU 2014-16-Derivatives and Hedging: Determining Whether the Host contract in a Hybrid Financial Instrument issued in the Form of a Share is More Akin to Debt or to Equity. Certain classes of shares include features that entitle the holders to preferences and rights (such as conversion rights, redemption rights, voting powers and liquidation and dividend payment preferences) over the other shareholders. Shares that include embedded derivative features are referred to as hybrid financial instruments, which must be separated from the host contract and accounted for as a derivative if certain criteria are met. This ASU is effective for fiscal years and interim periods within those fiscal years beginning after December 15, 2015
	Other recent accounting pronouncements issued by the FASB, the American Institute of Certified Public Accountants, and the Securities and Exchange Commission did not or are not believed by management to have a material impact on the Company's present or future financial statements.

Property_and_Equipment_Tables

Property and Equipment (Tables)	9 Months Ended
	Dec. 31, 2014
Property, Plant and Equipment [Abstract]
Schedule of property and equipment		31-Dec-14		Mar-14
	Computer equipment	$	1539-	$	-
	Furniture and fixtures		0-		-
			-		-
	Accumulated depreciation		565-		-
	Net	$	974-	$	-

Intangibles_Tables

Intangibles (Tables)	9 Months Ended
	Dec. 31, 2014
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of intangible assets		31-Dec-14		31-Mar-14
	HempTech Product Technology	$	100,000	$	-
	Trademarks		825		-
			-		-
	Accumulated Amortization		-9,531		-
	Intangibles, Net	$	91,294	$	-

Stock_Options_and_Awards_Table

Stock Options and Awards (Tables)	9 Months Ended
	Dec. 31, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Schedule of stock options and stock awards vested						Weighted Average				Remaining
		Options		Options		Intrinsic		Exercise		Contractual
		Outstanding		Vested		Value		Price		Term
	Options, March 31, 2014		0		0
	Granted		8,350,000		37,500		$0		$ 0.0262	3.46 yrs
			0		0
	Forfeited		0
	Options, December 31, 2014		8,350,000		37,500
Schedule of option expense		Awards		Awards
		Outstanding		Vested
	Options, March 31, 2014		0		0
	Granted		4,600,000		0
	Exercised		0		0
	Forfeited		0		0
	Options, December 31, 2014		4,600,000		0

Accrued_Expenses_Tables

Accrued Expenses (Tables)	9 Months Ended
	Dec. 31, 2014
Accrued Liabilities, Current [Abstract]
Schedule of accrued expenses		31-Dec-14		31-Mar-14
	Accrued salaries and payroll taxes	$	1,154,172	$	1,030,071
	Accrued interest		138,609		594,590
	Accrued penalties				-
		$	1,292,781	$	1,089,530

History_of_Company_and_Nature_

History of Company and Nature of Business (Detail Textuals) (USD $)	9 Months Ended	0 Months Ended
	Dec. 31, 2014	Dec. 05, 2014	Oct. 30, 2014	Oct. 06, 2014
			acre	acre
History Of Company And Nature Of Business [Line Items]
Monthly leasing fee	$1,440
Commercial Lease Agreement
History Of Company And Nature Of Business [Line Items]
Term of lease agreement		5 years
Term of renewation of lease agreement		3 years
Master lease agreement
History Of Company And Nature Of Business [Line Items]
Monthly leasing fee		575,000
Term of lease		5 years
NutraCann Labs Inc.
History Of Company And Nature Of Business [Line Items]
Present yearly usage for oil (in kilograms)	1,000-2,000
Present yearly value for oil	200,000,000
Global Nutraceutical market projected to be in excess by 2015	200,000,000,000
Value of current US Nutraceutical and Dietary supplement market	42,000,000,000
HempTech Corp
History Of Company And Nature Of Business [Line Items]
Contract price for turnkey technology	1,500,000
Monthly leasing fee	190,000
Term of lease	5 years
Futureland Properties, LLC
History Of Company And Nature Of Business [Line Items]
Percentage of ownership subsidiary				100.00%
Area of land purchased in southern Colorado				240
Area of land cosed in southern Colorado			237
American Green | Revenue sharing agreement
History Of Company And Nature Of Business [Line Items]
Monthly leasing fee	$150
American Green | Revenue sharing agreement | Maximum
History Of Company And Nature Of Business [Line Items]
Transaction cost per machine	2
American Green | Revenue sharing agreement | Minimum
History Of Company And Nature Of Business [Line Items]
Transaction cost per machine	1.5

Basis_of_Presentation_Business2

Basis of Presentation, Business and Summary of Significant Accounting Policies (Detail Textuals)	9 Months Ended
	Dec. 31, 2014
Accounting Policies [Abstract]
Depreciation method for Property and Equipment	straight-line method
Estimated useful lives for Property and Equipment	three to seven years

Going_Concern_Detail_Textuals

Going Concern (Detail Textuals) (USD $)	3 Months Ended		9 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2014	Dec. 31, 2013	Mar. 31, 2014	Mar. 31, 2013
Liquidity Disclosure [Abstract]
Net loss	($167,996)	($52,730)	($816,542)	($208,677)
Cumulative net loss	6,860,324		6,860,324		6,063,422
Cash	150,794		150,794		2,000	244,637
Working capital deficit	$1,099,308		$1,099,308

Property_and_Equipment_Details

Property and Equipment (Details) (USD $)	Dec. 31, 2014	Mar. 31, 2014
Property, Plant and Equipment [Line Items]
Property and equipment Gross
Accumulated depreciation	565
Net	974
Computer equipment
Property, Plant and Equipment [Line Items]
Property and equipment Gross	1,539
Furniture and fixtures
Property, Plant and Equipment [Line Items]
Property and equipment Gross	$0

Intangibles_Details

Intangibles (Details) (USD $)	Dec. 31, 2014	Mar. 31, 2014
Goodwill and Intangible Assets Disclosure [Abstract]
HempTech Product Technology	$100,000
Trademarks	825
Intangibles, Gross
Accumulated Amortization	-9,531
Intangibles, Net	$94,169

Intangibles_Details_Textuals

Intangibles (Details Textuals) (USD $)	3 Months Ended	9 Months Ended	0 Months Ended	1 Months Ended
	Dec. 31, 2014	Dec. 31, 2014	2-May-14	Apr. 30, 2014
Acquired Finite-Lived Intangible Assets [Line Items]
Amortization expense	$6,726	$9,531
Product Technology
Acquired Finite-Lived Intangible Assets [Line Items]
Useful life of acquired assets		15 years
Trademarks
Acquired Finite-Lived Intangible Assets [Line Items]
Useful life of acquired assets		15 years
MedTest, Inc. | Product Technology
Acquired Finite-Lived Intangible Assets [Line Items]
Number of common stock issued in acquisition			5,000,000
Amount paid in acquisition			100,000
Hemptech Corp., URVape, Inc., and CB Scientific, Inc. | Trademarks
Acquired Finite-Lived Intangible Assets [Line Items]
Value of intangible assets acquired				$825

Stock_Options_and_Awards_Detai

Stock Options and Awards (Details) (USD $)	9 Months Ended
	Dec. 31, 2014
Options Outstanding
Options, March 31, 2014	0
Granted	8,350,000
Exercised	0
Forfeited	0
Options, December 31, 2014	8,350,000
Options Vested
Options, March 31, 2014	0
Granted	37,500
Exercised	0
Forfeited
Options, December 31, 2014	37,500
Weighted Average Intrinsic Value	$0
Weighted Average Exercise Price	$0.03
Remaining Contractual Term	3 years 5 months 16 days

Stock_Options_and_Awards_Detai1

Stock Options and Awards (Details 1)	9 Months Ended
	Dec. 31, 2014
Awards Outstanding
Options, March 31, 2014	0
Granted	4,600,000
Exercised	0
Forfeited	0
Options, December 31, 2014	4,600,000
Options, March 31, 2014	0
Granted	0
Exercised	0
Forfeited	0
Options, December 31, 2014	0

Stock_Options_and_Awards_Detai2

Stock Options and Awards (Detail Textuals) (USD $)	3 Months Ended	9 Months Ended
	Dec. 31, 2014	Dec. 31, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Amortization of stock awards	$27	$22
Option Expense	17,951	33,235
Stock Awards Expense	$8,164	$15,778

Accrued_Expenses_Details

Accrued Expenses (Details) (USD $)	Dec. 31, 2014	Mar. 31, 2014
Accrued Liabilities, Current [Abstract]
Accrued salaries and payroll taxes	$1,154,172	$1,030,071
Accrued interest	138,609	594,590
Accrued penalties
Accrued Expenses, Total	$1,292,781	$1,089,530

Related_Parties_Disclosures_De

Related Parties Disclosures (Detail Textuals) (Saeed (Sam) Talari, USD $)	Dec. 31, 2014	Mar. 31, 2014	Apr. 01, 2010
Saeed (Sam) Talari
Related Party Transaction [Line Items]
Initial balance of promissory note			$306,319
Interest bearing percentage			5.00%
Balance due to related party	205,748	299,118
Accrued interest	$67,511	$45,048

Employment_Agreements_Detail_T

Employment Agreements (Detail Textuals) (Employment Agreement, USD $)	0 Months Ended		1 Months Ended		0 Months Ended	1 Months Ended
	Jan. 01, 2012	Apr. 15, 2014	Apr. 21, 2014	Apr. 24, 2014	15-May-14	Jun. 18, 2014	Dec. 31, 2014	Dec. 31, 2013
Mr. Sam Talari
Employment Agreements [Line Items]
Term of agreement	3 years
Extended term of agreement	1 year
Termination of agreement notice period description	within 90 days of the end of any periods
Base salary per month	$9,371
Percentage of increase in salary per annum	5.00%
Accrued salaries payable							1,096,393	900,733
Mr. Cameron Cox
Employment Agreements [Line Items]
Term of agreement		3 years
Extended term of agreement		1 year
Termination of agreement notice period description		within 90 days of the end of any periods
Base salary per month		3,000
Percentage of increase in salary per annum		5.00%
Mr. Kevin Defant
Employment Agreements [Line Items]
Term of agreement			3 years
Extended term of agreement			1 year
Termination of agreement notice period description			within 90 days of the end of any periods
Base salary per month			2,000
Percentage of increase in salary per annum			5.00%
Mr. Bill Short
Employment Agreements [Line Items]
Term of agreement				3 years
Extended term of agreement				1 year
Termination of agreement notice period description				within 90 days of the end of any periods
Base salary per month				3,000
Percentage of increase in salary per annum				5.00%
Mr. Derek Lebahn
Employment Agreements [Line Items]
Term of agreement					3 years
Extended term of agreement					1 year
Termination of agreement notice period description					within 90 days of the end of any periods
Base salary per month					2,000
Percentage of increase in salary per annum					5.00%
Mr. Charles Steinberg
Employment Agreements [Line Items]
Term of agreement					3 years
Extended term of agreement					1 year
Termination of agreement notice period description					within 90 days of the end of any periods
Base salary per month					2,000
Percentage of increase in salary per annum					5.00%
Mr. Joseph Kelly
Employment Agreements [Line Items]
Term of agreement						3 years
Extended term of agreement						1 year
Termination of agreement notice period description						within 90 days of the end of any periods
Base salary per month						1,600
Percentage of increase in salary per annum						5.00%
Mr. Andrew Marlatt
Employment Agreements [Line Items]
Term of agreement						3 years
Extended term of agreement						1 year
Termination of agreement notice period description						within 90 days of the end of any periods
Base salary per month						2,000
Percentage of increase in salary per annum						5.00%
Mr. Richard Buck
Employment Agreements [Line Items]
Term of agreement						3 years
Extended term of agreement						1 year
Termination of agreement notice period description						within 90 days of the end of any periods
Base salary per month						$2,400
Percentage of increase in salary per annum						5.00%

Office_Space_Detail_Textuals

Office Space (Detail Textuals) (USD $)	9 Months Ended
	Dec. 31, 2014
Office Space [Abstract]
Office space costs, per month	$1,440

Stockholders_Equity_Detail_Tex

Stockholders' Equity (Detail Textuals) (USD $)	0 Months Ended	1 Months Ended	0 Months Ended
	13-May-14	Aug. 29, 2014	2-May-14	Dec. 31, 2014	Mar. 31, 2014
Stockholders Equity Note [Line Items]
Preferred stock, shares authorized				100,000,000	100,000,000
Preferred stock, par value (in dollars per share)				$0.00	$0.00
Common stock, shares authorized				1,900,000,000	1,900,000,000
Common stock, par value (in dollars per share)				$0.00	$0.00
Common stock, shares issued				453,973,966	446,373,966
Common stock, shares outstanding				453,973,966	446,373,966
Shares issued in exchange for Services	1,000,000	1,600,000
Value of shares issued in exchange for Services	$19,000	$41,000
Stock Exchange Agreement | MedTest, Inc.
Stockholders Equity Note [Line Items]
Number of common shares exchanged in the agreement			5,000,000
Number of shares issued for share exchange			1,500,000
Additional shares issued for benchmarks			3,500,000

Subsequent_Events_Detail_Textu

Subsequent Events (Detail Textuals) (USD $)	9 Months Ended	0 Months Ended	1 Months Ended
	Dec. 31, 2014	Dec. 05, 2014	Jan. 20, 2015
			acre
Subsequent Event [Line Items]
Monthly leasing fee	$1,440
Commercial Lease Agreement
Subsequent Event [Line Items]
Term of renewation of lease agreement		3 years
Subsequent Events | Commercial Lease Agreement | GPS La Vita, Inc
Subsequent Event [Line Items]
Area of land lease out			5
Total Area Of Land			200
Term of lease			5 years
Monthly leasing fee			50,000
Monthly leasing fee per acer			$10,000
Obligated period to buy back property			36 months
Cumulative costs of funds per Annum			10.00%
Subsequent Events | Commercial Lease Agreement | Maximum
Subsequent Event [Line Items]
Term of renewation of lease agreement			5 years
Subsequent Events | Commercial Lease Agreement | Minimum
Subsequent Event [Line Items]
Term of renewation of lease agreement			3 years